A large phase 3 clinical trial for cystic fibrosis patients has concluded, showing that a combination of two new cystic fibrosis drugs modestly improved lung function and offered better health outcomes for some patients. Now, scientists have shown that one of these drugs counteracts the intended beneficial molecular effect of the other.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/bwV8x2bhNfY/140723152019.htm
Unsuspected characteristics of new cystic fibrosis drugs found, offering potential paths to more effective therapies
23 July 2014
Return